Search | Clinical Trials Finder

Conditions: Hypertension, COVID
Interventions: ACEI/ARB, Non-ACEI/ARB, ACEI, ARB; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 22,213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: Telmisartan, Standard of Care Regimen; Drug · Other
Lead sponsor: Tyler J Curiel; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: High Blood Pressure
Interventions: Thiazide Treatment Group, Intensified Thiazide Treatment Group, Combination Medication Treatment Group; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 59 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Covid19
Interventions: Telmisartan Oral Product, Placebo; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Heart Failure, Systolic, Frailty
Interventions: sacubitril/valsartan, Angiotensin II Receptor Blockers; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Abdominal Aortic Aneurysm
Interventions: Telmisartan, Placebo; Drug
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 50 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Ovarian Cancer
Interventions: Telmisartan; Drug
Lead sponsor: Tyler J Curiel; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Manchester, New Hampshire

Conditions: Stroke
Interventions: Telmisartan, Metformin, Cilostazol; Drug
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 21 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Hypertension, Diabetic Nephropathies
Interventions: telmisartan, losartan; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 47
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Lancaster, California + 41 more

Conditions: COVID-19
Interventions: Telmisartan 40mg, Placebo; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: HIV-1 Infection
Interventions: Telmisartan; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 8 more

Conditions: Hypertension
Interventions: Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 101
States / cities: Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more

Conditions: Alzheimer's Disease
Interventions: Telmisartan 20mg, Telmisartan 40mg, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 30 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Endothelial Dysfunction
Interventions: Telmisartan; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 50 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: GVHD
Interventions: Telmisartan; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Hypertension
Interventions: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more

Conditions: Hypertension
Interventions: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more

Conditions: Hypertension
Interventions: telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 100
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more

Conditions: Hypertension
Interventions: Telmisartan & Hydrochlorothiazide, Losartan & Hydrochlorothiazide, ABPM; Drug · Procedure
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 69
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Carmichael, California + 57 more

Search by objective public record fields.

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

Telmisartan in Prostate Cancer

Treating Nocturnal Hypertension and Nocturia in African American Men

INvestigating TELmisartin Study

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

Health Evaluation in African Americans Using RAS Therapy

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)